Navigation Links
Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
Date:8/21/2013

Raleigh, NC (PRWEB) August 21, 2013

Clinverse, Inc., a global technology and eclinical commerce network for clinical trials, announced today the addition of Denis Connaghan as Chief Executive Officer. Denis brings more than 25 years of substantial commercialization experience across industry sectors including technology, healthcare, insurance, life sciences and IT.

Prior to joining Clinverse, Denis served as a management consultant and in interim executive roles at GMA Healthcare, Infina Connect and several other life science IT and services companies. Additionally, he served as the CEO of etrials Worldwide, an eclinical solutions provider to pharmaceutical companies, prior to its acquisition by Merge Healthcare.

“I’m thrilled to join such a fast-paced, growing company,” expressed Connaghan. “Clinverse’s FLS platform is an industry-first and continues to outpace the industry in terms of innovation. We are well positioned to build on this solid technology foundation, and I look forward to working with the Clinverse team to capitalize on my global and industry expertise to drive additional opportunities in the clinical trial services market.”

With the announcement of Denis as CEO, Tim Immel, founder and former CEO of Clinverse, will take on the role of Chief Product Officer. In his new position, Tim will dedicate 100 percent of his commitment and direct attention to pursuing product excellence and ensuring the company maintains and grows its undisputed lead in the area of financial lifecycle systems for the clinical trials industry.

“Of all the many responsibilities I have had at Clinverse, none has been more important to the business or more gratifying to me personally than to design and build the exceptional products and services that we offer, products that fill an important yet unmet need in the marketplace,” said Immel. “Denis’s leadership is critical to our long-term success as we continue taking Clinverse to the heights we all envision, while delivering the highest quality service to clients.”

About Clinverse, Inc.
Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay®, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11041323.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Robert Farrell Joins Bionovos Board of Directors
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. First Choice Rehabilitation Specialists Joins Select Medical
6. Excel Life Sciences Joins DATATRAKs Connect Partner Program
7. Marina Biotech, Inc. Joins OTCQX
8. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
9. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
10. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port business ... Wistar Institute, and Sanguis, launched by a trio of students from the University of ... developing a treatment for a chronic viral infection and its associated diseases, with the ...
(Date:1/20/2017)... MA (PRWEB) , ... January ... ... leader in Less Exposure Surgery (LES®) Technologies, announced today the next evolution ... PedFuse Pedicle Screw System platform). In contrast to the competition, SpineFrontier is ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
Breaking Biology Technology:
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
Breaking Biology News(10 mins):